(Total Views: 623)
Posted On: 06/11/2022 2:38:58 AM
Post# of 148988
An interesting read on NAFLD/NASH.
What negative factors for NASH progression mentioned in the article does leronlimab downregulate? Almost all of them - NLRP3, IL-1b, TNF-a, IL-6, IL-18, NLRP1, ASC, caspase-1, GSDMD, NF-kB, ATP, ROS.
They propose a variety of NLRP3 inhibitors as possibilities for NAFLD/NASH but none of them have approval. Leronlimab has a much broader reach than NLRP3 for NASH. An example ROS can induce NLRP3 activation, but leronlimab can downregulate ROS and it's other negative effects besides NLRP3.
Quote:
The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment
https://www.frontiersin.org/articles/10.3389/...80496/full
What negative factors for NASH progression mentioned in the article does leronlimab downregulate? Almost all of them - NLRP3, IL-1b, TNF-a, IL-6, IL-18, NLRP1, ASC, caspase-1, GSDMD, NF-kB, ATP, ROS.
They propose a variety of NLRP3 inhibitors as possibilities for NAFLD/NASH but none of them have approval. Leronlimab has a much broader reach than NLRP3 for NASH. An example ROS can induce NLRP3 activation, but leronlimab can downregulate ROS and it's other negative effects besides NLRP3.
(10)
(0)Scroll down for more posts ▼
